Clinical Trials Logo

Stress Disorders, Traumatic clinical trials

View clinical trials related to Stress Disorders, Traumatic.

Filter by:

NCT ID: NCT02384369 Not yet recruiting - Clinical trials for Stress Disorders, Post-Traumatic

Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder

PTSD
Start date: June 2016
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled study of SNC-102 in adult subjects with cPTSD, added to pre-existing treatment that includes prazosin with or without other psychotropic drugs. Subjects will be treated with SNC-102 tablets or matching placebo on a BID basis for 8 weeks. Subjects will be evaluated for the symptoms of combat-related posttraumatic stress disorder (cPTSD) as measured by the Clinician Administered PTSD Scale (CAPS-5), compared with the response to placebo.

NCT ID: NCT02370576 Not yet recruiting - Clinical trials for Depressive Disorder, Major

The Effect of Traumatic Childbirth on the Incidence of PTSD and Other Major Postpartum Psychopathology

Start date: March 2015
Phase: N/A
Study type: Observational [Patient Registry]

Determination of incidence and prevalence of PTSD and other types of psychopathology (such as anxiety and affective disorders) after traumatic birth experiences and elucidation of salient risk factors in the local population sample- by prospective follow-up.

NCT ID: NCT02336802 Not yet recruiting - Panic Disorder Clinical Trials

Threat-Avoidance Learning in Anxiety Patients

AVOID
Start date: January 2016
Phase: N/A
Study type: Observational

Anxiety disorders are characterized by exaggerated levels of fear that are not proportional to the actual level of threat. More specifically, anxiety patients have marked deficits in the downregulation of fear reactions during situations of objective safety. Pre-clinical research on Pavlovian fear conditioning and extinction has discovered that fear downregulation stems from areas in the prefrontal cortex (the ventro-medial prefrontal cortex, vmPFC) that recruit intercalated cells in the amygdala to inhibit its central nucleus, which is responsible for a variety of behavioral expressions of fear (Milad & Quirk, 2012). Accordingly, functional magnetic resonance imaging studies (fMRI) revealed reduced vmPFC activity coupled with increased fear reactions during situations of objective safety in anxiety patients (Milad et al., 2009). Another core symptom of anxiety disorders, though much less investigated, is the excessive avoidance of situations that trigger the fears. These 'safety behaviors' often interfere with daily life activities and valued goals in life, and they are thought to perpetuate the exaggerated levels of fear by precluding opportunities to learn that the feared situations are actually not dangerous. Surprisingly, experimental research on avoidance behaviors in anxiety patients is virtually non-existent. This experiment modifies the Pavlovian fear conditioning procedure to include avoidance, and explores the behavioral and neural processes of this type of fear regulation in anxiety patients (trans-diagnostically) and healthy individuals.

NCT ID: NCT02336568 Not yet recruiting - PTSD Clinical Trials

The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD)

Start date: March 2015
Phase: Phase 4
Study type: Interventional

Oxytocin (OT) - a neurohormone and neuromodulator which is mainly synthesized in the hypothalamus - is a mediator stress regulation and improves social bonding. Recently, several theoretical studies suggested that PTSD patients have abnormal functioning of the OT system. According to these theories, dysfunction in the oxytocin system may modulate the interpersonal impairment that characterizes PTSD, and therefore intranasal OT may potentially relieve these symptoms. In two current studies that were conducted in Rambam health care we found that a single dose of intranasal OT reduces anxiety and irritability symptoms, and enhances emotional empathy and compassion, in patients with PTSD. The main goal of this study is to examine the effects of 21-days intranasal Oxytocin on clinical symptoms and social function in these patients.

NCT ID: NCT02033395 Not yet recruiting - Clinical trials for Post Traumatic Stress Disorder

A Correlation Between Hair Cortisol Levels and the Development of Post Traumatic Stress Disorder (PTSD)

Start date: January 2014
Phase: N/A
Study type: Observational

This observational study follows subjects who have been exposed to a traumatic event and are at risk of developing PTSD symptoms. Participants are recruited within six hours of a traumatic event, and, starting from the recruitment session, are then examined on six set points of time within a period of thirteen months. The examinations include both biological studies of cortisol in hair, blood and saliva, and psychological examinations and questionaires that assess the development and severity of PTSD symptoms. The novel method of sampling hair cortisol allows investigators to retroactively estimate the mean levels of blood cortisol during the tree months prior to the sampling. The study aims at further illuminating the correlation between cortisol levels both prior and following a traumatic event, and the development and severity of PTSD symptoms

NCT ID: NCT01940549 Not yet recruiting - Clinical trials for Post-traumatic Stress Disorder (PTSD)

Transcranial Direct Current Stimulation (tDCS) Enhancement of Trauma-focused Therapy for Posttraumatic Stress Disorder

Start date: October 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to test whether transcranial direct current stimulation (tDCS) can enhance the clinical efficacy of trauma-focused therapy for posttraumatic stress disorder.

NCT ID: NCT01914861 Not yet recruiting - Clinical trials for Posttraumatic Stress Disorders

Cortisol Diurnal Variation and the Risk for Developing Post Traumatic Stress Disorder

Start date: July 2013
Phase: N/A
Study type: Observational

The purpose of this study is to examine a possible link between the time of day of exposure to a traumatic event and the risk of developing post-traumatic stress disorder. Clinical and biological correlates will also be examined from this perspective.

NCT ID: NCT01684085 Not yet recruiting - Clinical trials for Post Traumatic Stress Disorder

Explanation About Sleep in Post Trauma Patients

Start date: October 2012
Phase: N/A
Study type: Interventional

This study is designed to test the effect of an explanation about the first sleep following trauma exposure, on the development of Post Traumatic Stress Disorder (PTSD) in the months following the traumatic event.

NCT ID: NCT01162044 Not yet recruiting - Clinical trials for Posttraumatic Stress Disorder

Examining an Emergency Room Intervention for the Prevention of Post Traumatic Stress Disorder (PTSD)

Start date: November 2010
Phase: N/A
Study type: Interventional

PTSD is a common and distressing possible outcome following exposure to a traumatic event. Recent studies show that memory processes may be central to the development of the disorder, and interrupting the consolidation of traumatic memories may prevent the disorder from developing. Specifically the use of a visual spatial task has been shown to reduce a key characteristic of PTSD, intrusions, in non-clinical populations. This study aims to administer a visual spatial task to recent trauma survivors in the Emergency Room, and compare PTSD and symptoms development in these patients as compared to a control group who did not carry out the task. The study hypothesizes that the task will result in less PTSD, lower levels of intrusions, dissociation and pain.

NCT ID: NCT00908440 Not yet recruiting - Clinical trials for Posttraumatic Stress Disorder

Decision Aid in Veterans With Posttraumatic Stress Disorder

Start date: June 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effects of a decision aid on veterans with posttraumatic stress disorder (PTSD) presenting for care. The investigators' primary hypothesis is that patients assigned to use the decision aid will demonstrate improved quality of decisions regarding PTSD treatment relative to patients assigned to usual care. Improved decision quality will be examined by assessing patient's knowledge of treatments, evaluation of the risk and benefits, ability to arrive at a decision, and certainty about that decision. The investigators' secondary hypothesis is that patients assigned to the decision aid will be more satisfied with their care and more compliant with their care compared to patients assigned to receive usual care. The investigators will also determine whether patients assigned to the decision aid, relative to patients assigned to usual care, are more likely to receive evidence-based treatments for PTSD and experience reductions in PTSD symptoms.